Fortress Biotech, Inc. (FBIO)
NASDAQ: FBIO · Real-Time Price · USD
1.880
-0.110 (-5.53%)
At close: Nov 13, 2026, 4:00 PM EST
1.875
-0.005 (-0.27%)
After-hours: Nov 13, 2026, 7:30 PM EST
Fortress Biotech Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 68.75 | 61.24 | 56.68 | 64.99 | 73.07 | 68.79 |
Other Revenue | 1.24 | 2.02 | 1 | 19.52 | 2.67 | - |
| 69.99 | 63.26 | 57.68 | 84.51 | 75.74 | 68.79 | |
Revenue Growth | 12.34% | 9.69% | -31.76% | 11.58% | 10.11% | 50.86% |
Cost of Revenue | 23.72 | 32.83 | 77.76 | 128.96 | 165.65 | 160.95 |
Gross Profit | 46.28 | 30.44 | -20.09 | -44.45 | -89.91 | -92.16 |
Selling, General & Admin | 69.08 | 96.4 | 87.73 | 87.84 | 113.66 | 86.84 |
Research & Development | 3.02 | - | - | - | - | - |
Amortization of Goodwill & Intangibles | 4.13 | 4.26 | 3.42 | 3.77 | - | - |
Other Operating Expenses | - | - | -4.55 | - | - | - |
Operating Expenses | 76.23 | 100.66 | 86.6 | 91.61 | 113.66 | 86.84 |
Operating Income | -29.96 | -70.22 | -106.69 | -136.06 | -203.56 | -179 |
Interest Expense | -9.38 | -10.11 | -9.93 | -15.32 | -13.64 | -15.31 |
Interest & Investment Income | 4.08 | 2.49 | 2.68 | 3 | 1.4 | 0.65 |
Other Non Operating Income (Expenses) | 163.56 | 32.28 | 0.68 | 1.02 | 2.34 | -0.45 |
EBT Excluding Unusual Items | 128.3 | -45.56 | -113.25 | -147.35 | -213.46 | -194.11 |
Gain (Loss) on Sale of Investments | -0.03 | -15.1 | - | - | - | 39.29 |
Gain (Loss) on Sale of Assets | 0.19 | 27.13 | - | - | - | - |
Asset Writedown | - | - | -3.69 | -6.29 | - | - |
Other Unusual Items | 0.4 | - | -3.6 | - | - | -9.54 |
Pretax Income | 128.86 | -33.54 | -120.54 | -153.63 | -213.46 | -164.35 |
Income Tax Expense | 4.75 | -0.62 | 0.31 | 0.52 | 0.45 | 0.47 |
Earnings From Continuing Operations | 124.11 | -32.92 | -120.86 | -154.15 | -213.91 | -164.83 |
Net Income to Company | 124.11 | -32.92 | -120.86 | -154.15 | -213.91 | -164.83 |
Minority Interest in Earnings | -23.99 | 39.73 | 74.86 | 93.52 | 127.34 | 100.12 |
Net Income | 100.12 | 6.82 | -46 | -60.64 | -86.58 | -64.7 |
Preferred Dividends & Other Adjustments | 8.28 | 8.7 | 9.89 | 8.03 | 8.03 | - |
Net Income to Common | 91.84 | -1.88 | -55.89 | -68.67 | -94.61 | -64.7 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 33 | 28 | 21 | 8 | 6 | 5 |
Shares Outstanding (Diluted) | 34 | 28 | 21 | 8 | 6 | 5 |
Shares Change | 28.63% | 34.24% | 156.25% | 36.89% | 8.78% | 13.46% |
EPS (Basic) | 2.80 | -0.07 | -2.69 | -8.47 | -15.97 | -11.88 |
EPS (Diluted) | 2.68 | -0.07 | -2.69 | -8.47 | -15.97 | -11.88 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 125.75 | -65.78 | -80.19 | -128.29 | -182.12 | -121.11 |
Free Cash Flow Per Share | 3.67 | -2.36 | -3.86 | -15.82 | -30.74 | -22.23 |
Gross Margin | 66.11% | 48.11% | -34.82% | -52.60% | -118.70% | -133.97% |
Operating Margin | -42.80% | -111.00% | -184.98% | -160.99% | -268.76% | -260.21% |
Profit Margin | 131.21% | -2.97% | -96.91% | -81.25% | -124.91% | -94.06% |
Free Cash Flow Margin | 179.66% | -103.98% | -139.04% | -151.80% | -240.44% | -176.05% |
EBITDA | -25.45 | -65.56 | -102.22 | -130.06 | -196.18 | -173.9 |
EBITDA Margin | -36.36% | -103.63% | -177.24% | -153.89% | -259.00% | -252.79% |
D&A For EBITDA | 4.51 | 4.66 | 4.46 | 6 | 7.39 | 5.1 |
EBIT | -29.96 | -70.22 | -106.69 | -136.06 | -203.56 | -179 |
EBIT Margin | -42.80% | -111.00% | -184.98% | -160.99% | -268.76% | -260.21% |
Revenue as Reported | 69.99 | 63.26 | 57.68 | 84.51 | 75.74 | 68.79 |